Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Postoperative Period × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1 Head & Neck 1 Genitourinary 1 Endocrine 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Docetaxel 168 Gemcitabine 126 Prednisone 125 pembrolizumab 102 enzalutamide 100 Abiraterone Acetate 92 Nivolumab 86 Magnetic Resonance Spectroscopy 86 Cisplatin 86 Leuprolide 81 Radiotherapy 79 Sunitinib 77 Carboplatin 73 Specimen Handling 61 Radiosurgery 56 Paclitaxel 54 Goserelin 53 Androgen Antagonists 50 bicalutamide 49 Ipilimumab 49 apalutamide 47 Bevacizumab 44 Sorafenib 43 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 42 cabozantinib 40 cabazitaxel 40 Everolimus 40 abiraterone 39 atezolizumab 35 Axitinib 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02075060 2017-04-06

IPOI vs IPOP

Poitiers University Hospital

Phase 2 Unknown

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡